We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can ALHC's Raised 2026 Outlook Offset Heavier Second-Half Spending?
Read MoreHide Full Article
Key Takeaways
ALHC raised its 2026 revenue, membership, adjusted gross profit and EBITDA outlooks.
ALHC expects Q3 EBITDA to fall as Care Anywhere, AI and market-launch spending accelerate.
ALHC's medical benefit ratio improved to 86.3%, its lowest level since becoming publicly traded.
Alignment Healthcare, Inc. (ALHC - Free Report) strengthened its 2026 outlook after a second quarter marked by higher membership, better-than-expected earnings and improving medical-cost performance. The first half also produced $106 million of adjusted EBITDA, up 60% year over year.
The trade-off is timing. Management plans additional clinical, artificial intelligence and expansion spending in the second half, with the heaviest impact in the third quarter. That leaves investors weighing durable operating momentum against a near-term step-down in profitability.
Here's a look at the company's solid track record of topping earnings estimates.
Image Source: Zacks Investment Research
ALHC’s Second-Quarter Results Beat Expectations
Second-quarter earnings were 17 cents per share, up from 7 cents a year earlier and 30.8% above the Zacks Consensus Estimate. Revenues increased 31.6% to $1.34 billion and topped the consensus mark by 2%.
Health plan membership reached about 294,100, up 31.5% year over year and above the prior guidance range of 288,000-290,000. Adjusted gross profit rose 35.3% to $182.9 million, lifting adjusted gross margin to 13.7% from 13.3%.
Management raised the midpoint of its full-year guidance metrics after the first-half performance. The company now expects 2026 revenues of $5.195 billion-$5.225 billion and membership of 298,000-301,000.
Image Source: Zacks Investment Research
Adjusted gross profit is projected at $630 million-$650 million, while adjusted EBITDA is expected at $145 million-$163 million. Humana Inc. (HUM - Free Report) offers relevant Medicare Advantage context, as it recently reaffirmed expectations for roughly 25% individual Medicare Advantage membership growth in 2026.
Third-Quarter Spending Tests ALHC’s Progress
The third-quarter outlook shows the cost of that growth agenda. ALHC expects adjusted EBITDA of $20 million-$30 million, versus $68.1 million in the second quarter, as Care Anywhere hiring, artificial intelligence projects and 2027 market-launch preparation accelerate.
Management expects only about 30% of full-year adjusted EBITDA to be generated in the second half, compared with roughly 40% in the prior year. Additional second-half investment is expected to reach the double-digit millions across medical costs and selling, general and administrative expenses.
AI Investment Could Expand ALHC’s Leverage
The newest version of ALHC’s AVA risk-stratification model can identify the 10% of members expected to account for nearly 70% of hospital admissions over the next 30 days. That targeting can help Care Anywhere teams direct clinical resources toward members with the highest near-term risk.
The company is also expanding automation across claims processing, chart preparation, risk adjustment and reconciliation. First-half adjusted selling, general and administrative expenses fell to 8.7% of revenues, improving 40 basis points year over year despite continued systems investment.
Medical-Cost Trends Remain the Key ALHC Variable
Adjusted medical benefit ratio improved 40 basis points year over year to 86.3%, the company’s lowest level since becoming publicly traded. Excluding the new-member final sweep, the ratio was 86.7% and remained favorable to guidance.
The third quarter is expected to bring a seasonally higher ratio because of greater new-member acuity, a flatter Part D cost slope and added clinical investment. UnitedHealth Group Incorporated (UNH - Free Report) reported a second-quarter 2026 medical cost ratio of 86.7%, illustrating how medical-cost discipline remains central across large managed-care platforms.
ALHC’s Ratings Reflect Event-Driven Uncertainty
ALHC’s raised outlook provides a cushion against heavier spending, but the second-half mix leaves less room for execution errors in utilization management, hiring and technology implementation. The near-term case therefore depends on whether those investments translate into operating leverage without disrupting medical-cost control.
The stock currently carries a Zacks Rank #3 (Hold). Its Growth Score of A, Value Score of B and VGM Score of A point to favorable growth and blended style characteristics, while the Momentum Score of D indicates weaker near-term price momentum. The combination supports a measured stance rather than a definitive call based on one quarter.
View the Zacks #1 Rank List
Image: Bigstock
Can ALHC's Raised 2026 Outlook Offset Heavier Second-Half Spending?
Key Takeaways
Alignment Healthcare, Inc. (ALHC - Free Report) strengthened its 2026 outlook after a second quarter marked by higher membership, better-than-expected earnings and improving medical-cost performance. The first half also produced $106 million of adjusted EBITDA, up 60% year over year.
The trade-off is timing. Management plans additional clinical, artificial intelligence and expansion spending in the second half, with the heaviest impact in the third quarter. That leaves investors weighing durable operating momentum against a near-term step-down in profitability.
Here's a look at the company's solid track record of topping earnings estimates.
Image Source: Zacks Investment Research
ALHC’s Second-Quarter Results Beat Expectations
Second-quarter earnings were 17 cents per share, up from 7 cents a year earlier and 30.8% above the Zacks Consensus Estimate. Revenues increased 31.6% to $1.34 billion and topped the consensus mark by 2%.
Health plan membership reached about 294,100, up 31.5% year over year and above the prior guidance range of 288,000-290,000. Adjusted gross profit rose 35.3% to $182.9 million, lifting adjusted gross margin to 13.7% from 13.3%.
Raised Guidance Confirms ALHC’s Operating Momentum
Management raised the midpoint of its full-year guidance metrics after the first-half performance. The company now expects 2026 revenues of $5.195 billion-$5.225 billion and membership of 298,000-301,000.
Image Source: Zacks Investment Research
Adjusted gross profit is projected at $630 million-$650 million, while adjusted EBITDA is expected at $145 million-$163 million. Humana Inc. (HUM - Free Report) offers relevant Medicare Advantage context, as it recently reaffirmed expectations for roughly 25% individual Medicare Advantage membership growth in 2026.
Third-Quarter Spending Tests ALHC’s Progress
The third-quarter outlook shows the cost of that growth agenda. ALHC expects adjusted EBITDA of $20 million-$30 million, versus $68.1 million in the second quarter, as Care Anywhere hiring, artificial intelligence projects and 2027 market-launch preparation accelerate.
Management expects only about 30% of full-year adjusted EBITDA to be generated in the second half, compared with roughly 40% in the prior year. Additional second-half investment is expected to reach the double-digit millions across medical costs and selling, general and administrative expenses.
AI Investment Could Expand ALHC’s Leverage
The newest version of ALHC’s AVA risk-stratification model can identify the 10% of members expected to account for nearly 70% of hospital admissions over the next 30 days. That targeting can help Care Anywhere teams direct clinical resources toward members with the highest near-term risk.
The company is also expanding automation across claims processing, chart preparation, risk adjustment and reconciliation. First-half adjusted selling, general and administrative expenses fell to 8.7% of revenues, improving 40 basis points year over year despite continued systems investment.
Medical-Cost Trends Remain the Key ALHC Variable
Adjusted medical benefit ratio improved 40 basis points year over year to 86.3%, the company’s lowest level since becoming publicly traded. Excluding the new-member final sweep, the ratio was 86.7% and remained favorable to guidance.
The third quarter is expected to bring a seasonally higher ratio because of greater new-member acuity, a flatter Part D cost slope and added clinical investment. UnitedHealth Group Incorporated (UNH - Free Report) reported a second-quarter 2026 medical cost ratio of 86.7%, illustrating how medical-cost discipline remains central across large managed-care platforms.
ALHC’s Ratings Reflect Event-Driven Uncertainty
ALHC’s raised outlook provides a cushion against heavier spending, but the second-half mix leaves less room for execution errors in utilization management, hiring and technology implementation. The near-term case therefore depends on whether those investments translate into operating leverage without disrupting medical-cost control.
The stock currently carries a Zacks Rank #3 (Hold). Its Growth Score of A, Value Score of B and VGM Score of A point to favorable growth and blended style characteristics, while the Momentum Score of D indicates weaker near-term price momentum. The combination supports a measured stance rather than a definitive call based on one quarter.
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.